RightFit
RecruitingNot applicable

Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma

Breathprinting (E-Nose) Technology to Measure Response to Treatment of Malignant Pleural Mesothelioma (MPM) Through MPM-Specific Volatile Organic Compounds Detected in Exhalates

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
30 Years to 85 Years
Sex
All sexes
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study tests whether an electronic nose (E-Nose) can use breath patterns to track how people respond to standard treatment for malignant pleural mesothelioma, a cancer of the lining around the lungs. It is for people ages 30–85 who were recently diagnosed. Researchers will compare changes in breath patterns with scan results and blood markers of the cancer.

The researchers are doing this study to test the ability of a new technology called breathprinting, or electronic nose (E-Nose), to measure how people respond to standard treatment for malignant pleural mesothelioma (MPM). The researchers will study how E-Nose breathprints change over time as people receive standard treatment for MPM. They will also look at how changes in people's E-Nose breathprints compare to changes in their standard imaging scans and in biomarkers of MPM in their blood.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • Be 30–85 years old.
  • Have a recent diagnosis of malignant pleural mesothelioma.
  • Have no history of chest cancer or cancer elsewhere that could spread to the lining around the lungs, such as breast, stomach, colon, or pancreas cancer.
  • Sign and date a study consent form before any study procedures, and sign the standard consent form for surgery to remove tissue.

Who can't join

  • Be younger than 30 or older than 85 at the first outpatient visit.
  • Have a history of cancer in the chest or elsewhere that could spread to the lungs or their lining.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: * Aged 30-85 years * No history of thoracic cancer or extrathoracic cancer potentially involving pleural metastases (i.e., breast, gastric, colon, or pancreas cancer) * Recent diagnosis of MPM * Documented, signed, and dated informed consent, obtained before any procedures, for the proposed research study, and signed standard surgical consent for surgical resection Exclusion Criteria: * Aged \<30 or \>85 years at the first outpatient visit * History of thoracic or extrathoracic cancer that puts the subject at risk for pleural or pulmonary metastases

Study sites (7)

NJ

NY